Cargando…

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir

BACKGROUND: The prognostic significance of the common BCR-ABL transcripts like e13a2 (b2a2) and e14a2 (b3a2) in Chronic myeloid leukemia (CML) has been reported from patients treated with different tyrosine kinase inhibitors but its impact on clinical response and overall survival remains still unex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azad, Niyaz A, Shah, Zafar A, Pandith, Arshad A, Khan, Mosin S, Rasool, Roohi, Rasool, Javed, Aziz, Shiekh A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103580/ https://www.ncbi.nlm.nih.gov/pubmed/29936718 http://dx.doi.org/10.22034/APJCP.2018.19.6.1479

Ejemplares similares

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Frequency of BCR-ABL Transcript Types in Syrian CML Patients
por: Farhat-Maghribi, Sulaf, et al.
Publicado: (2016)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Loss of Gadd45b accelerates BCR-ABL-driven CML
por: Sha, Xiaojin, et al.
Publicado: (2018)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML
por: Gaballa, Salem, et al.
Publicado: (2020)

Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for ‘minimal residual disease’ assessment in chronic myeloid leukemia
por: Azad, Niyaz A., et al.
Publicado: (2018)

Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
por: Agarwal, Mohan B.
Publicado: (2014)

Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
por: Mahmoud, Hossam K, et al.
Publicado: (2009)

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML
por: Liu, Yanjun, et al.
Publicado: (2021)

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
por: Burchert, Andreas
Publicado: (2014)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
por: Zizioli, Daniela, et al.
Publicado: (2021)

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
por: Zhang, Jingru, et al.
Publicado: (2018)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report
por: Iqbal, Zafar, et al.
Publicado: (2004)

Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors
por: Minami, Y, et al.
Publicado: (2012)

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
por: Klamová, Hana, et al.
Publicado: (2013)

Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients
por: Gaafar, Taghrid Mohamed, et al.
Publicado: (2015)

The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
por: Ru, Yi, et al.
Publicado: (2016)

Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML)
por: Zhang, Jianchao, et al.
Publicado: (2023)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
por: Bennett, John M., et al.
Publicado: (2014)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML
por: Lima, Maria Carolina P., et al.
Publicado: (2023)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL
por: Mc Gee, Margaret M., et al.
Publicado: (2001)

ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance
por: Wang, Zhiqiang, et al.
Publicado: (2014)

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
por: Spiess, Birgit, et al.
Publicado: (2019)

AMP‐activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR‐ABL protein in CML cells
por: Koyama, Daisuke, et al.
Publicado: (2020)

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
por: Langhammer, Melanie, et al.
Publicado: (2023)

Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant
por: Jin, Bei, et al.
Publicado: (2018)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)

A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor
por: Yang, Tzu-Yi, et al.
Publicado: (2013)

Correction: ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4bkkqd7pgppajbrg886p8lfj27